Loading data
GMEDNYSE
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.94 bn USD | 2.52 bn USD | 1.57 bn USD | 1.02 bn USD | 958.1 m USD |
| Cost of revenue | 957.8 m USD | 1.04 bn USD | 548.17 m USD | 263.73 m USD | 239.22 m USD |
| Gross profit | — | — | 1.02 bn USD | 759.12 m USD | 718.88 m USD |
| Research and development expense | 147.25 m USD | 163.75 m USD | 124.01 m USD | 73.02 m USD | 97.35 m USD |
| Selling, general and administrative expense | 1.18 bn USD | 981.36 m USD | 643.84 m USD | 432.12 m USD | 408.15 m USD |
| Operating profit | 479.82 m USD | 165.99 m USD | 133.14 m USD | 227.95 m USD | 171.95 m USD |
| Profit before tax | 605.07 m USD | 120.72 m USD | 165.39 m USD | 243.02 m USD | 180.41 m USD |
| Income tax expense | 67.2 m USD | 17.74 m USD | 42.52 m USD | 52.85 m USD | 31.22 m USD |
| Net income (reported basis) | 537.87 m USD | 102.98 m USD | 122.87 m USD | 190.17 m USD | 149.19 m USD |
| Net income attributable to common shareholders | 537.87 m USD | 102.98 m USD | 122.87 m USD | 190.17 m USD | 149.19 m USD |
| Basic earnings per share | 3.98 USD/share | 0.76 USD/share | 1.09 USD/share | 1.89 USD/share | 1.48 USD/share |
| Diluted earnings per share | 3.92 USD/share | 0.75 USD/share | 1.07 USD/share | 1.85 USD/share | 1.44 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.